New Data Is Likely To Add Fuel To The Drug-Eluting-Stent Debate
This article was originally published in The Gray Sheet
Executive Summary
New trial data presented at the American College of Cardiology annual meeting could be another obstacle to drug-eluting-stent manufacturers' efforts to reverse a year-long sales slump
You may also be interested in...
J&J Medical Device Revenue Up, But Cypher Sales Are Still A Drag
Johnson & Johnson's device revenue growth is still hindered by declining sales of the Cypher sirolimus-eluting coronary stent, the company reported during its first-quarter earnings call April 17
J&J Medical Device Revenue Up, But Cypher Sales Are Still A Drag
Johnson & Johnson's device revenue growth is still hindered by declining sales of the Cypher sirolimus-eluting coronary stent, the company reported during its first-quarter earnings call April 17
COURAGE Suggests Stents Do Not Benefit Stable Coronary Disease Patients
Results of the highly anticipated COURAGE trial challenge the widespread assumption that stents improve outcomes in patients with stable coronary disease, but several observers believe the findings' impact on the stent market will be modest